D J Costa1, P Marteau2, M Amouyal1, L K Poulsen3, E Hamelmann4, M Cazaubiel5, B Housez5, S Leuillet5, M Stavnsbjerg6, P Molimard7, S Courau7, J Bousquet8. 1. Primary Care Department, University of Medicine, Montpellier I University, Montpellier, France. 2. University Paris Diderot, Sorbonne Paris Cité, APHP, Department of Hepato-gastro-enterology, Hôpital Lariboisière, Paris, France. 3. Allergy Clinic, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark. 4. University Children's Hospital, Ruhr-University Bochum, Department of Pediatrics, Bochum, Germany. 5. Biofortis, Mérieux NutriSciences Company, Saint-Herblain, France. 6. Global Regulatory and External Affairs, Chr. Hansen A/S, Hørsholm, Denmark. 7. Merck Consumer Health, Merck Médication Familiale, Dijon, France. 8. 1] Department of Respiratory Diseases, University Hospital, Hôpital Arnaud de Villeneuve, Montpellier, France [2] Inserm, CESP Centre for Research in Epidemiology and Population Health, Respiratory and Environmental Epidemiology team, Villejuif, France.
Abstract
BACKGROUND/ OBJECTIVES: An imbalance between Th1 and Th2 cells is involved in allergic rhinitis (AR) that may be improved by probiotics. To test the efficacy of the probiotic Lactobacillus paracasei subsp. paracasei LP-33, a double-blind, placebo-controlled, randomized trial was carried out in patients with AR to grass pollen treated withloratadine and presenting altered quality of life. SUBJECTS/ METHODS:Subjects with persistent AR, symptomatic during the grass pollen season, and a positive skin test or specific immunoglobulin E to grass pollens were included by general practitioners (GPs). All received loratadine for 5 weeks. The primary end point was the improvement in Rhinitis Quality of Life (RQLQ) global score at the fifth week of LP-33 consumption compared with placebo (in addition to loratadine). Secondary end points included nasal and ocular symptoms (individual and total symptom scores), visual analogue scale and time of first exacerbation of the symptoms when loratadine was stopped. RESULTS:A total of 425 subjects were included. Using intent-to-treat analysis, the RQLQ global score decreased significantly more in the LP-33 group than in the placebo group (P=0.0255, difference=-0.286 (95% confidence interval (CI): -0.536; -0.035)). No significant differences were noted for the change of the rhinitis total symptom score 5 global score between groups (P=0.1288, difference=-0.452 (95% CI: -1.036; 0.132)). Significant differences in ocular symptoms (RQLQ) were observed between groups (P=0.0029, difference=-0.4087 (95% CI: -0.6768; -0.1407)). CONCLUSIONS: This study performed by GPs shows that LP-33 improves the quality of life of subjects with persistent AR who are currently being treated with an oral H1-antihistamine. Whereas nasal symptoms had not changed, ocular symptoms had consistently improved.
RCT Entities:
BACKGROUND/ OBJECTIVES: An imbalance between Th1 and Th2 cells is involved in allergic rhinitis (AR) that may be improved by probiotics. To test the efficacy of the probiotic Lactobacillus paracasei subsp. paracaseiLP-33, a double-blind, placebo-controlled, randomized trial was carried out in patients with AR to grass pollen treated with loratadine and presenting altered quality of life. SUBJECTS/ METHODS: Subjects with persistent AR, symptomatic during the grass pollen season, and a positive skin test or specific immunoglobulin E to grass pollens were included by general practitioners (GPs). All received loratadine for 5 weeks. The primary end point was the improvement in Rhinitis Quality of Life (RQLQ) global score at the fifth week of LP-33 consumption compared with placebo (in addition to loratadine). Secondary end points included nasal and ocular symptoms (individual and total symptom scores), visual analogue scale and time of first exacerbation of the symptoms when loratadine was stopped. RESULTS: A total of 425 subjects were included. Using intent-to-treat analysis, the RQLQ global score decreased significantly more in the LP-33 group than in the placebo group (P=0.0255, difference=-0.286 (95% confidence interval (CI): -0.536; -0.035)). No significant differences were noted for the change of the rhinitis total symptom score 5 global score between groups (P=0.1288, difference=-0.452 (95% CI: -1.036; 0.132)). Significant differences in ocular symptoms (RQLQ) were observed between groups (P=0.0029, difference=-0.4087 (95% CI: -0.6768; -0.1407)). CONCLUSIONS: This study performed by GPs shows that LP-33 improves the quality of life of subjects with persistent AR who are currently being treated with an oral H1-antihistamine. Whereas nasal symptoms had not changed, ocular symptoms had consistently improved.
Authors: G Walter Canonica; Jean Bousquet; Geneviève Van Hammée; Claus Bachert; Stephen R Durham; Ludger Klimek; Joaquim Mullol; Paul B Van Cauwenberge Journal: Respir Med Date: 2006-05-24 Impact factor: 3.415
Authors: Jean Bousquet; Claus Bachert; Giorgio W Canonica; Thomas B Casale; Alvaro A Cruz; Richard J Lockey; Torsten Zuberbier Journal: J Allergy Clin Immunol Date: 2009-08-05 Impact factor: 10.793
Authors: Jean Bousquet; Claus Bachert; Giorgio W Canonica; Joaquim Mullol; Paul Van Cauwenberge; Carsten Bindslev Jensen; Wystke J Fokkens; Johannes Ring; Paul Keith; Gokul Gopalan; Richard Lorber; Torsten Zuberbier Journal: Int Arch Allergy Immunol Date: 2010-06-18 Impact factor: 2.749
Authors: J Bousquet; C Bachert; G W Canonica; J Mullol; P Van Cauwenberge; C Bindslev Jensen; W J Fokkens; J Ring; P Keith; R Lorber; T Zuberbier Journal: Allergy Date: 2009-07-14 Impact factor: 13.146
Authors: Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek Journal: Int Forum Allergy Rhinol Date: 2018-02 Impact factor: 3.858
Authors: Mariona Pascal; Marina Perez-Gordo; Teresa Caballero; Maria M Escribese; M Natividad Lopez Longo; Olga Luengo; Luis Manso; Victor Matheu; Elena Seoane; Miguel Zamorano; Moisés Labrador; Cristobalina Mayorga Journal: Front Immunol Date: 2018-07-17 Impact factor: 7.561